Who is sponsoring NCT00752141?

NCT00752141 is sponsored by Watson Pharmaceuticals.

What drugs are being tested in NCT00752141?

Interventions in NCT00752141: oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo.

What condition does NCT00752141 study?

NCT00752141 studies Healthy Volunteers.

Is NCT00752141 still recruiting?

NCT00752141 is currently completed. Last updated 22 September 2011.

Last reviewed 2011-09-22 · How we verify

NCT00752141

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

Completed Phase 1 Last updated 22 September 2011

What this trial tests

Phase 1 trial testing oxybutynin chloride immediate-release in Healthy Volunteers in 153 participants. Completed.

Timeline

1 September 2008

Primary endpoint
1 October 2008

Quick facts

Lead sponsor	Watson Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Enrollment	153
Start date	1 September 2008
Primary completion	1 October 2008
Sites	6 locations across United States

Drugs / interventions tested

oxybutynin chloride immediate-release — full drug profile →
oxybutynin chloride topical gel
placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Watson Pharmaceuticals — full company profile →

Who can join

Adults 60 to 79, any sex, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Measure of accuracy of delayed recall name-phase association test
Time frame: one week

Sponsor's own description

The purpose of this study is to explore the possible cognitive effects of oxybutynin tablets and oxybutynin gel.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.
Kay GG, Staskin DR, MacDiarmid S, McIlwain M, et al · · 2012 · cited 20× · PMID 22909146 · DOI 10.1007/bf03261924

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00752141 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Watson Pharmaceuticals
Last refreshed: 22 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00752141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing